Oncofetal Biology: From Fundamental Mechanisms to Emerging Therapeutic Opportunities
MedComm – Oncology, Volume 5, Issue 2, June 2026.Oncofetal biology provides a transformative framework for understanding cancer initiation, progression, and therapeutic intervention. This review synthesizes the core molecular mechanisms connecting embryonic development and tumorigenesis from a multidisciplinary standpoint and outlines future research trajectories and clinical applications, and we aim
Yang Liu +3 more
wiley +1 more source
Search strategies for “mHealth interventions to increase cancer screening rates in Latino populations: A scoping review” [PDF]
, 2021 Famojuro, Oluwaseun +6 more
core +1 more source
Birth weight for gestational age (BW/GA) has been associated with a risk of adverse health outcomes. Biological indices of pregnancy complications, maternal mid-pregnancy serum biomarkers and placental pathology may shed light on these associations, but ...
core
Refining early detection of hepatocellular carcinoma: The promise of the GALAD score. [PDF]
World J GastroenterolPrakash HS +3 more
europepmc +1 more source
Liver International, Volume 46, Issue 6, June 2026.ABSTRACT Background and Aims To evaluate the prognostic significance of pathological response in patients with initially unresectable hepatocellular carcinoma (uHCC) who underwent salvage resection after successful conversion with lenvatinib, anti‐PD‐1 antibodies, and locoregional therapy (LPLRT).
Qi‐Yu Chi +9 more
wiley +1 more source
Yolk sac tumor: what are the particularities? A case report [PDF]
We report the case of a 25-year-old girl admitted for management of an abdomino-pelvic mass. Radiological and biological findings were in favour of a malignant ovarian secretory tumor.
A. Chebil +6 more
core +1 more source
Durable response to FOLFOX plus serplulimab in AFP-producing gastric adenocarcinoma with liver metastases: a case report and literature review. [PDF]
Front ImmunolJin Y, Fu L, Zhao Y, Tong Z, Tan Y.
europepmc +1 more source
From Theory to Practice: Which Biomarkers Are Ready for Predicting Response in Advanced HCC?
Liver International, Volume 46, Issue 6, June 2026.ABSTRACT Systemic therapies for advanced hepatocellular carcinoma (HCC) have expanded considerably with the advent of tyrosine kinase inhibitors, immune checkpoint inhibitors and immunotherapy–anti‐angiogenic combinations. However, despite this therapeutic diversification, first‐line treatment selection remains largely empirical, as few biomarkers are ...
Marie Decraecker +3 more
wiley +1 more source
Case report: Spatiotemporal HER2 heterogeneity in AFP-producing gastric cancer: navigating long-term survival with molecularly-guided therapy in a refractory case. [PDF]
Front ImmunolDiao Y, Yin H, Sun X, Dong Q, Zhang J.
europepmc +1 more source
Liver International, Volume 46, Issue 6, June 2026.ABSTRACT Evidence supporting the safety and efficacy of immune checkpoint inhibitors (ICI) before liver transplantation (LTx) in hepatocellular carcinoma (HCC) is increasing, but risks of graft rejection and tumour recurrence remain major concerns. We evaluated post‐transplant outcomes across 10 European centres using data from the multinational LITCHI
Ulrike Bauer +22 more
wiley +1 more source